Experts discuss the 5-year efficacy and safety outcomes of polatuzumab in diffuse large B-cell lymphoma (DLBCL), highlighting ...

For example, one of the most common treatments for diffuse large B-cell lymphoma is R-CHOP. This combines a drug called rituximab (Riabni, Rituxan, Ruxience, Truxima) with three chemotherapy drugs ...

Diffuse large B-cell lymphoma is an aggressive cancer, but it is treatable. The initial treatment often puts it into remission, which means there are no longer any signs or symptoms of the cancer.

A rare case has been reported of diffuse large B-cell lymphoma (DLBCL) presenting initially as cold agglutinin disease (CAD). The report, published in the Kaohsiung Journal of Medical Sciences, ...

Your treatment and outlook are linked to the type and stage of your lymphoma. There are many types of NHL, but the most common are B-cell lymphomas and T-cell lymphomas. B-cell lymphomas make up ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

The company said that ZAMTO Cell is designed to target both CD19 and CD20, which could improve treatment efficacy.

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Non-Hodgkin lymphomas either begin in B cells or T cells ... characterize the lymphoma and guide treatment decisions. Accurately diagnosing T-cell lymphoma often takes time.

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

Experts discuss how the 5-year outcomes of polatuzumab have influenced its position in current NCCN guidelines for diffuse ...

It's an important piece of info to get, because each type of this cancer acts differently and has its own treatment. To help figure out what type of B-cell lymphoma you have, your doctor will do a ...